Table 2.
Responses by age subgroup
| Age <70 years | Age ≥70 years | |||
|---|---|---|---|---|
| Carfilzomib group (n = 293) | Control Group (n = 281) | Carfilzomib group (n = 103) | Control group (n = 115) | |
| Best overall response, n (%)a | ||||
| Stringent complete response | 40 (13·7) | 16 (5·7) | 16 (15·5) | 1 (0·9) |
| Complete response | 46 (15·7) | 16 (5·7) | 24 (23·3) | 4 (3·5) |
| Very good partial response | 116 (39·6) | 83 (29·5) | 35 (34·0) | 40 (34·8) |
| Partial response | 50 (17·1) | 73 (26·0) | 18 (17·5) | 31 (27·0) |
| Overall response rate, % (95% CI)a | 86·0 (81·5–89·8) | 66·9 (61·1–72·4) | 90·3 (82·9–95·2) | 66·1 (56·7–74·7) |
| Median duration of response, months (95% CI) | 30·4 (25·1–36·1) | 23·1 (17·3–32·3) | 23·3 (17·2–29·4) | 16·7 (12·9–30·5) |
CI, confidence interval.
a
Patients evaluated for overall response rate had a best overall response of partial response or better.